No Data
Overview of the lifting of restrictions on tradable A-shares | March 11.
According to the Zhitong Finance APP, on March 11th, 4 listed companies had their restricted shares lifted, with a total market value of approximately 0.39 billion yuan. The specific situation of the restricted shares lifted today is as follows: Stock Abbreviation Stock Code Restricted Share Type Lifted Shares Zhuzhou Qianjin Pharmaceutical 600479 Stock-based Incentive Restricted Circulation 2.721 million Jinhua Chunguang Technology 603657 Stock-based Incentive Restricted Circulation 1.0043 million Fosai Technology 301529 Extended Restricted Lockup Circulation 10.5252 million Liyuan Technology 688565 1.3369000005 million
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Zhuzhou Qianjin Pharmaceutical (600479.SH): As a popular film, "Ne Zha 2" has brought significant customer traffic and box office growth to Qianjin Cinemas.
On February 13, Gelonghui reported that Zhuzhou Qianjin Pharmaceutical (600479.SH) stated on the investor interaction platform that the attendance rate of Qianjin Cinema during the Spring Festival in 2025 has increased significantly compared to the same period last year. "Ne Zha 2," as a popular film, has brought noticeable customer traffic and box office growth to Qianjin Cinema.
Zhuzhou Qianjin Pharmaceutical (600479.SH): has conducted extensive connections with a well-known domestic AI company.
On February 13, Gelonghui reported that Zhuzhou Qianjin Pharmaceutical (600479.SH) stated on the investor interaction platform that the company has conducted extensive connections with well-known domestic AI companies and is actively exploring AI application scenarios. An AI technology middle platform has been established to support the comprehensive integration and innovation of AI with the company’s Business, and AI applications such as marketing AI assistants, system process assistants, and contract risk identification assistants have been developed. In the future, the company will closely follow the trends in AI development, actively research new technologies such as deepseek, and timely introduce the latest relevant technologies to promote the company's comprehensive intelligent transformation.
Zhuzhou Qianjin Pharmaceutical (600479.SH): plans to acquire 28.92% equity of Qianjin Xiangjiang Pharmaceutical for 0.623 billion yuan and 68.00% equity of Qianjin Xieli Pharmaceutical.
On February 10, Gelonghui reported that Zhuzhou Qianjin Pharmaceutical (600479.SH) announced that the listed company plans to purchase 28.92% of the shares of Zhuzhou Guotou and Liebang Kantai in Qianjin Xiangjiang Pharmaceutical by issuing shares, and intends to purchase 68.00% of the shares held by Zhuzhou Guotou and Huang Yang, along with 21 natural persons in Qianjin Xieli Pharmaceutical, through a combination of issuing shares and paying Cash. The source of funds for the cash consideration in this acquisition of the targeted assets will be the company's own funds, with a transaction price of 0.623 billion yuan. All targeted companies for this transaction are controlled subsidiaries of listed companies. Qianjin Xiangjiang Pharmaceutical mainly engages in the chemical synthesis of Active Pharmaceutical Ingredient.
Zhuzhou Qianjin Pharmaceutical (600479.SH): The tadalafil tablets have received a notification of approval for the supplemental application for the Pharmaceutical.
On January 20, Gelonghui reported that Zhuzhou Qianjin Pharmaceutical (600479.SH) announced that its subsidiary Hunan Qianjin Xiangjiang Pharmaceutical Co., Ltd. received the approval notice from the National Medical Products Administration for the supplementary application of Tadalafil tablets (5mg). Tadalafil tablets are a type 5 phosphodiesterase (PDE5) inhibitor developed by Eli Lilly and Co, with the brand name Cialis, and are a first-line treatment for male erectile dysfunction. With the continuous in-depth clinical research, the National Medical Products Administration has approved the indication for Tadalafil new tablets for benign prostatic hyperplasia.